Y-mAbs Therapeutics, Inc.984241109US984241109507/11/2025To approve, on a non-binding advisory vote basis, the compensation of the Company's named executive officers as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTES4031230.0000000FOR4031230.000000FORMerus N.V.N5749R100NL001160626412/09/2025Non-binding advisory proposal to approve certain compensation arrangementsSECTION 14A SAY-ON-PAY VOTES4188961.0000000FOR4188961.000000FORAbivax SA00370M103US00370M103605/11/2026Approve Compensation of Sylvie Gregoire, Chairwoman of the BoardSECTION 14A SAY-ON-PAY VOTES772473.0000000AGAINST772473.000000AGAINSTAbivax SA00370M103US00370M103605/11/2026Approve Compensation of Marc de Garidel, CEOSECTION 14A SAY-ON-PAY VOTES772473.0000000AGAINST772473.000000AGAINSTInsmed Incorporated457669307US457669307505/13/2026An advisory vote on the 2025 compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES778118.0000000FOR778118.000000FORCytokinetics, Incorporated23282W605US23282W605705/27/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTES459548.0000000FOR459548.000000FORSpyre Therapeutics, Inc.00773J202US00773J202405/27/2026To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES518054.0000000FOR518054.000000FOROruka Therapeutics, Inc.687604108US687604108706/02/2026To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES370590.0000000FOR370590.000000FORViridian Therapeutics, Inc.92790C104US92790C104506/02/2026To approve, on an advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES1662358.0000000FOR1662358.000000FORViridian Therapeutics, Inc.92790C104US92790C104506/02/2026To approve, on an advisory basis, the frequency of holding an advisory vote on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES1662358.0000000ONE YEAR1662358.000000FORAssembly Biosciences, Inc.045396207US045396207006/04/2026Approval, on a non-binding advisory basis, of our named executive officers' compensation.SECTION 14A SAY-ON-PAY VOTES640452.0000000FOR640452.000000FOREdgewise Therapeutics, Inc.28036F105US28036F105706/04/2026Conduct an advisory vote on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES6256954.0000000FOR6256954.000000FORScholar Rock Holding Corporation80706P103US80706P103006/04/2026To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES250013.0000000AGAINST250013.000000AGAINSTTango Therapeutics, Inc.87583X109US87583X109006/04/2026To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES1781524.0000000FOR1781524.000000FORApogee Therapeutics, Inc.03770N101US03770N101906/09/2026Approval, on a non-binding advisory basis, of the compensation of our named executive officers as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTES165263.0000000FOR165263.000000FORMirum Pharmaceuticals, Inc.604749101US604749101306/15/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTES560305.0000000FOR560305.000000FORVaxcyte, Inc.92243G108US92243G108506/15/2026Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES829655.0000000FOR829655.000000FORNuvalent, Inc.670703107US670703107506/16/2026To approve, on an advisory basis, the compensation paid to our named executive officers.SECTION 14A SAY-ON-PAY VOTES3140580.0000000FOR3140580.000000FOROlema Pharmaceuticals, Inc.68062P106US68062P106606/17/2026Approval, on an advisory basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES7387705.0000000FOR7387705.000000FORStructure Therapeutics Inc.86366E106US86366E106406/17/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTES734522.0000000FOR734522.000000FOREyePoint, Inc.30233G209US30233G209306/18/2026To approve, on an advisory basis, the compensation paid to the Company's named executive officers as disclosed in the accompanying proxy statement.SECTION 14A SAY-ON-PAY VOTES2335686.0000000FOR2335686.000000FORRevolution Medicines, Inc.76155X100US76155X100006/18/2026To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on-Pay").SECTION 14A SAY-ON-PAY VOTES5094491.0000000FOR5094491.000000FORTarsus Pharmaceuticals, Inc.87650L103US87650L103506/25/2026To hold an advisory vote to approve, on a non-binding basis, our named executive officer compensation.SECTION 14A SAY-ON-PAY VOTES2002080.0000000FOR2002080.000000FORInventiva SA46124U107US46124U107906/30/2026Approve Compensation of Mark Pruzanski, Chairman of the BoardSECTION 14A SAY-ON-PAY VOTES3952691.0000000AGAINST3952691.000000AGAINSTInventiva SA46124U107US46124U107906/30/2026Approve Compensation of Frederic Cren, CEO until September 30, 2025SECTION 14A SAY-ON-PAY VOTES3952691.0000000AGAINST3952691.000000AGAINSTInventiva SA46124U107US46124U107906/30/2026Approve Compensation of Andrew Obenshain, CEO from October 1, 2025SECTION 14A SAY-ON-PAY VOTES3952691.0000000AGAINST3952691.000000AGAINSTInventiva SA46124U107US46124U107906/30/2026Approve Compensation of Pierre Broqua, Vice-CEO until June 30, 2025SECTION 14A SAY-ON-PAY VOTES3952691.0000000AGAINST3952691.000000AGAINST